AIToday
AI in HealthcareAI Business & IndustrySiliconANGLE AIPublished: Nov 20, 2026, 10:01 JST

Boltz raises $110 million to speed up AI drug discovery

Send on LINE
Boltz raises $110 million to speed up AI drug discovery

3 Key Points

  1. What happened

    Boltz raised $110 million in a Series A led by Bessemer, with backers including Greycroft and Andreessen Horowitz, to expand its AI drug-discovery models.

  2. Why it matters

    The funding will let Boltz grow its headcount and buy more computing infrastructure, helping it keep pace with larger AI labs moving into biology research, the company said.

WHO IT HITSPharmaceutical research teams that screen hundreds of thousands of molecules per project may get faster, cheaper binding-affinity data from Boltz's models, potentially shortening early-stage drug discovery. The startup counts six of the world's 20 largest pharma companies as clients.

Not sure about something? Ask the AI

Questions and answers are published on this page.

Summaries like this, every morning.

Context & Analysis

Boltz's raise comes as general-purpose AI labs have pushed into biology. Over the past year, Anthropic and OpenAI have each introduced models highly adapted to biology research tasks, and Boltz says the extra computing infrastructure from this round should help it keep up with them.

The startup's pitch rests on a narrower workflow: finding small molecule hits, the faint early clues that tell researchers where to focus. In an internal test across 10 challenging and therapeutically-relevant targets, BoltzMol-1 found hits for six of them. Boltz also offers BoltzProt-1, which generates tens of thousands of protein designs from that hit data and screens each one for drug potential. The company says its protein evaluation mechanism showed “higher success” than several competing models in internal tests.

Boltz sells access to its algorithms via an API billed by token usage, and customer token consumption has grown by a factor of 50 since the two models launched in June. That usage, plus six of the world's 20 largest pharma companies as clients, suggests the tools are finding paid use even before the next generation of models is ready. Boltz says those new algorithms are already in training and “showing substantial improvements” over its current models.

FAQ
How does BoltzMol-1 speed up drug discovery?
It generates binding affinity data by reviewing only a few dozen promising molecules instead of the hundreds of thousands usually needed, cutting analysis time.
Who are Boltz's customers?
Boltz counts six of the world's 20 largest pharmaceutical companies as clients, and its token consumption has grown by a factor of 50 since its models launched in June.
What will Boltz use the funding for?
The company will use the new funding to grow its headcount and procure more computing infrastructure.
SiliconANGLE AIRead Original Article
Send on LINE

AI news that matters for your work, delivered every morning.

Pick your industry and the AI tools you use, and get news related to your work every day.

Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →

Ask AI

Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.

Questions and answers are published on this page.

Related Articles

Next articleNvidia, partners build end-to-end AI ecosystem with Epson